Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

Key Inclusion Criteria: * Age 21 to 75 * Biopsy-confirmed NASH with fibrosis stage F2 or F3 per NASH CRN System and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation. * Qualifying biopsy must be either within 6 months of screening visit or obtained during screening period Key Exclusion Criteria: * Have poorly controlled high blood pressure * Have type 1 diabetes or poorly controlled type 2 diabetes. * History of cirrhosis or evidence of cirrhosis by clinical, imaging, or liver biopsy evaluation * Are planning to try to lose weight during the conduct of the study. * Have a BMI \<25 kg/m2 Other inclusion and exclusion criteria may apply.